At the 14th World Congress of the International Pancreas and Islet Transplant Association (IPITA), UC San Francisco faculty presented the latest in islet transplantation, and shared exciting progress in stopping islet and tissue rejection through regulatory T cells (Tregs) and creating new sources of insulin-producing beta cells.
T1D Exchange, the first program of the new nonprofit organization Unitio, has received funding from JDRF to study the use of metformin—a drug used as first-line treatment for type 2 diabetes—in combination with standard insulin therapy in overweight adolescents with type 1 diabetes.
A new, phase II clinical trial is being launched to evaluate the safety and efficacy of imatinib as a novel therapy for new-onset type 1 diabetes. Imatinib, also known as Gleevec, is a successful cancer drug that previously reversed type 1 diabetes in animal models.
A recent study in non-clinically depressed adults with type 2 diabetes compared three interventions to reduce Diabetes Distress and improve self-management. All three interventions utilized varying degrees of computer-assisted self-management.
Discovery of EHMT1’s role has tremendous implications for battle against obesity and related metabolic disorders, including insulin resistance. Shingo Kajimura, PhD, a researcher in the Diabetes Center and a member of the Department of Cell and Tissue Biology at UC San Francisco, has identified a gene vital to the development and function of brown fat cells.
Coursera, one of the leading providers of MOOCs (or massive open online courses) is now offering a free course on diabetes taught by faculty members from throughout UCSF’s professional schools: Medicine, Nursing, Pharmacy and Dentistry. Topics include epidemiology, diabetes diagnosis, nutritional strategies for self-management, the role of insulin in managing diabetes, effects of diabetes on oral/dental health, and current research in the field.
Mark Anderson, MD, PhD, and his colleagues have discovered a distinctive type of immune cell called an eTAC, which puts a damper on immune responses and could eventually lead to more effective treatments for autoimmune diseases including type 1 diabetes.
Executive Vice Chancellor and Provost Jeffrey Bluestone, PhD, was elected to the Institute of Medicine (IOM), one of the highest honors in the fields of health and medicine. The IOM recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
An experimental drug that has been studied for nearly 20 years continues to show effectiveness in about half of the patients who participated in a recent phase 2 clinical trial. The drug, Teplizumab -- also known as anti CD3 -- is designed to block the advance of Type 1 Diabetes in its earliest stages.
Four prevention trials are currently under way at dozens of sites around the country, including both Stanford and UCSF. Click here to read the article.
This month, Dean Schillinger, MD, was awarded the 2013 Public Health Communications Research Award by the American Public Health Association (APHA). The APHA Everett Rogers Award is given to an individual who has made an outstanding contribution to advancing the study and/or practice of public health communication. Dr Schillinger, Chief of the UCSF Division of General Internal Medicine at SF General Hospital, is widely recognized for his seminal work in the field of health literacy.